MedTrace Logo

Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

NCT03861702 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-04-18

Study results available
· View outcomes & findings →

Summary

This is a phase II, single-arm, open-label, clinical study to investigate the efficacy and tolerability of a combination of liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI) for treatment of patients with locally advanced pancreatic carcinoma (LAPC).

Conditions

  • Locally Advanced Pancreatic Carcinoma(LAPC)

Interventions

DRUG

FOLFOX regimen

FOLFOX (Oxaliplatin, Leucovorin, 5-Fluorouracil)

DRUG

Liposomal Irinotecan

Liposomal Irinotecan

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • Nelson Yee

    lead OTHER

Principal Investigators

  • Nelson Yee · Penn State Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-02
Primary Completion
2023-08-16
Completion
2024-09-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03861702 on ClinicalTrials.gov